3 Things You Should Expect in Gilead Sciences' Q3 Results

3 Things You Should Expect in Gilead Sciences' Q3 Results

Things are looking up for Gilead Sciences (NASDAQ: GILD) for the first time in quite a while. Although the big biotech stock fell in the first half of 2017, its share price is up big since late June. Gilead announced better-than-expected results for its second quarter in July. And the company announced a much-anticipated acquisition in August with its deal to buy Kite Pharma.

Gilead provides an update on its third-quarter performance after the market closes on Thursday, Oct. 26. Can the biotech keep its momentum going? Here are three things you should expect in Gilead's third-quarter results.

Image source: Getty Images.

Continue reading

Source: Fool.com